Phibronimal Health Corporation Class A (PAHC) Peer Comparison
$35.62
$-0.96
(-2.62%)
As on 11-Sep-2026 16:00EDT
Market cap
$1,553 Mln
Revenue (TTM)
$1,518 Mln
P/E Ratio
15.9
P/B Ratio
4
Div. Yield
1.2 %
Edit
| Phibronimal Health Corporation Class A (PAHC) | BridgeBio Pharma (BBIO) | Elanco Animal Health (ELAN) | Corcept Therapeutics (CORT) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
1,553 | 14,631 | 11,421 | 12,066 | 10,826 |
Revenue ($ Mln) |
1,518 | 692 | 5,020 | 831 | 777 |
Net Profit ($ Mln) |
99.72 | -696.24 | -199.00 | 54.90 | -191.64 |
Net Margin (%) |
6.57 | -100.64 | -3.96 | 6.61 | -24.68 |
RoE (%) |
29.72 | -- | -3.03 | 8.11 | -223.36 |
Price to Earnings |
15.87 | -- | -- | 248.04 | -- |
Price-To-Book |
4.05 | 123.68 | 1.79 | 17.29 | 131.04 |
Income Statement ($ Mln)
| Phibronimal Health Corporation Class A (PAHC) | BridgeBio Pharma (BBIO) | Elanco Animal Health (ELAN) | Corcept Therapeutics (CORT) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
|
Operating Revenue
|
1,518.09 | -- | -- | -- | -- |
|
Cost of Revenue
|
1,005.58 | -- | -- | -- | -- |
|
Gross Profit
|
511.71 | -- | -- | -- | -- |
|
Operating Expenses
|
312.50 | -- | -- | -- | -- |
|
Operating Profit (EBIT)
|
198.44 | -- | -- | -- | -- |
|
Other Income
|
-- | -- | -- | -- | -- |
|
Profit before Tax
|
137.35 | -- | -- | -- | -- |
|
Provision for Tax
|
37.63 | -- | -- | -- | -- |
|
Profit after Tax (Net Income)
|
99.72 | -- | -- | -- | -- |
|
Minority Interest
|
-- | -- | -- | -- | -- |
|
Consolidated Profit
|
-- | -- | -- | -- | -- |
Liabilities ($ Mln)
| Phibronimal Health Corporation Class A (PAHC) | BridgeBio Pharma (BBIO) | Elanco Animal Health (ELAN) | Corcept Therapeutics (CORT) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
385.48 | -- | -- | -- | -- |
|
Minority Interest
|
-- | -- | -- | -- | -- |
|
Non-Current Liabilities
|
799.30 | -- | -- | -- | -- |
|
Current Liabilities
|
316.47 | -- | -- | -- | -- |
|
Total Liabilities
|
1,501.24 | -- | -- | -- | -- |
Assets ($ Mln)
| Phibronimal Health Corporation Class A (PAHC) | BridgeBio Pharma (BBIO) | Elanco Animal Health (ELAN) | Corcept Therapeutics (CORT) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
565.74 | -- | -- | -- | -- |
|
Current Assets
|
935.51 | -- | -- | -- | -- |
|
Total Assets
|
1,501.24 | -- | -- | -- | -- |
|
Total Debt*
|
788.77 | -- | -- | -- | -- |
|
Net Current Assets
|
619.04 | -- | -- | -- | -- |
Cashflow ($ Mln)
| Phibronimal Health Corporation Class A (PAHC) | BridgeBio Pharma (BBIO) | Elanco Animal Health (ELAN) | Corcept Therapeutics (CORT) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
68.95 | -- | -- | -- | -- |
|
Cash Flow from Investing Activities
|
-71.46 | -- | -- | -- | -- |
|
Cash from Financing Activities
|
-6.56 | -- | -- | -- | -- |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| Phibronimal Health Corporation Class A (PAHC) | BridgeBio Pharma (BBIO) | Elanco Animal Health (ELAN) | Corcept Therapeutics (CORT) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
8.98 | -- | -- | -- | -- |
|
ROE (%)
|
29.72 | -- | -- | -- | -- |
|
ROA (%)
|
6.97 | -- | -- | -- | -- |
|
EBIT Margin (%)
|
-- | -- | -- | -- | -- |
|
Net Margin (%)
|
6.57 | -- | -- | -- | -- |
|
Cash Profit Margin (%)
|
-- | -- | -- | -- | -- |
Growth Ratios
| Phibronimal Health Corporation Class A (PAHC) | BridgeBio Pharma (BBIO) | Elanco Animal Health (ELAN) | Corcept Therapeutics (CORT) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
0.17 | -- | -- | -- | -- |
|
EBIT Growth (%)
|
-- | -- | -- | -- | -- |
|
Net Profit Growth (%)
|
106.61 | -- | -- | -- | -- |
|
EPS Growth (%)
|
1.05 | -- | -- | -- | -- |
|
Book Value Growth (%)
|
-- | -- | -- | -- | -- |
Valuation Ratios
| Phibronimal Health Corporation Class A (PAHC) | BridgeBio Pharma (BBIO) | Elanco Animal Health (ELAN) | Corcept Therapeutics (CORT) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
12.91 | -- | -- | -- | -- |
|
Price / Book Value
|
3.34 | -- | -- | -- | -- |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
8.43 | -- | -- | -- | -- |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| Phibronimal Health Corporation Class A (PAHC) | BridgeBio Pharma (BBIO) | Elanco Animal Health (ELAN) | Corcept Therapeutics (CORT) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
2.05 | -- | -- | -- | -- |
|
Short term debt to equity ratio
|
0.09 | -- | -- | -- | -- |
|
Current Ratio
|
2.96 | -- | -- | -- | -- |
|
Quick Ratio
|
1.27 | -- | -- | -- | -- |
|
Interest Coverage
|
3.89 | -- | -- | -- | -- |
Operating Efficiency Ratios
| Phibronimal Health Corporation Class A (PAHC) | BridgeBio Pharma (BBIO) | Elanco Animal Health (ELAN) | Corcept Therapeutics (CORT) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
15.73 | -- | -- | -- | -- |
|
Asset Turnover
|
1.06 | -- | -- | -- | -- |
|
Receivable days
|
56.15 | -- | -- | -- | -- |
|
Inventory Days
|
177.85 | -- | -- | -- | -- |
|
Payable days
|
48.22 | -- | -- | -- | -- |
|
Cash Conversion Cycle
|
185.79 | -- | -- | -- | -- |
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
